SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 39.64 |
| Enterprise Value ($M) | 30.49 |
| Book Value ($M) | 9.03 |
| Book Value / Share | 0.67 |
| Price / Book | 4.39 |
| NCAV ($M) | 8.50 |
| NCAV / Share | 0.63 |
| Price / NCAV | 4.66 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.50 |
| Return on Assets (ROA) | -1.12 |
| Return on Equity (ROE) | -1.67 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.15 |
| Current Ratio | 4.15 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 15.69 |
| Assets | 16.21 |
| Liabilities | 7.18 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| SCHEDULE 13G | Stonepine Capital Management, LLC | |||
| 13D | Sanderling Venture Partners VI LP | 18.30 | ||
| 13G/A | Soleus Private Equity Fund III, L.P. | 8.50 | ||
| 13G/A | Lytton Laurence W | 4.40 | -37.99 | |
| 13D/A | Valence Investments SPV VI, LLC | 9.00 | 4.67 | |
| 13G/A | Soleus Capital Master Fund, L.P. | 9.99 | 40.96 | |
| 13G/A | BML Investment Partners, L.P. | 2.10 | ||
| 13D/A | Orbimed Advisors Llc | 2.90 | 0.00 | |
| 13G | Aisling Capital V, LP | 5.10 | ||
| 13G | Flynn James E | 9.99 | 844.01 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,227 | 24,273 | 13.29 | |
| 1,530 | 22,853 | 6.69 | |
| 5,987 | 14,616 | 40.96 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BPTH – Bio-Path Holdings, Inc. | BTAI – BioXcel Therapeutics, Inc. |
| BYSI – BeyondSpring Inc. | CAPR – Capricor Therapeutics, Inc. |
| CARA – Cara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io